Related Experiment Video
Updated: Feb 26, 2026

Aversive Associative Learning and Memory Formation by Pairing Two Chemicals in Caenorhabditis elegans
Published on: June 23, 2022
Classics in Chemical Neuroscience: Memantine
Shahrina Alam1, Kaelyn Skye Lingenfelter1, Aaron M Bender1
1Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine , Nashville, Tennessee 37232, United States.
Memantine, a novel NMDA receptor antagonist, offers significant benefits for moderate to severe Alzheimer's disease (AD). This medication improves cognition, daily function, and delays institutionalization in AD patients.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Glutamatergic dysfunction plays a key role in AD pathogenesis.
- Memantine represents a novel therapeutic approach for AD.
Purpose of the Study:
- To review the historical significance of memantine in treating Alzheimer's disease.
- To provide an overview of memantine's synthesis, pharmacology, and metabolism.
- To highlight memantine's unique mechanism of action as an NMDA receptor antagonist.
Main Methods:
- Literature review of memantine's development and application.
- Analysis of memantine's pharmacological properties.
- Examination of clinical outcomes associated with memantine use.
Main Results:
- Memantine, approved in 2003, was the first NMDA receptor antagonist for moderate to severe AD.
- It acts as a moderate-affinity, uncompetitive, voltage-dependent NMDA antagonist with fast kinetics.
- Memantine, alone or with donepezil, improves cognition, behavior, daily functioning, and delays institutionalization.
Conclusions:
- Memantine is a landmark medication in Alzheimer's disease treatment.
- Its unique mechanism offers a valuable therapeutic option for managing AD symptoms.
- Memantine holds a significant place in the field of chemical neuroscience.
More Related Videos
18:01Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
Published on: August 18, 2008
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Treatment
Antiepileptic Drugs: Glutamate Antagonists
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...